Abstract

Ewing's sarcoma is one of the most frequent bone cancers in adolescence. Although multi-disciplinary therapy has improved the survival rate for localized tumors, a critical step is the development of new drugs to improve the long term outcome of recurrent and metastatic disease and to reduce side-effects of conventional therapy.
Here, we demonstrate that the small molecule RITA (Reactivation of p53 and Induction of Tumor cell Apoptosis, NSC652287) is highly effective in reducing growth and tumorigenic potential of Ewing's sarcoma cell lines. These effects occur both in the presence of wt-p53 as well as of mutant or truncated forms of p53, or in its absence, suggesting the presence of additional targets in this tumor histotype. Further experiments provided evidence that RITA modulates an important oncogenic mark of these cell lines, insulin like growth factor receptor 1 (IGF-1R). Particularly, RITA causes downregulation of IGF-1R protein levels. MDM2 degradative activity is involved in this phenomenon. Indeed, inhibition of MDM2 function by genetic or pharmacologic approaches reduces RITA sensitivity of Ewing's sarcoma cell lines. Overall, these data suggest that in the cell context of Ewing's sarcoma, RITA may adopt additional mechanism of action besides targeting p53, expanding its field of application. Noteworthy, these results envisage the promising utilization of RITA or its derivative as a potential treatment for Ewing's sarcomas.